Reaction
Small Intestinal Resection reporting signals
As of the last recalculation, Small Intestinal Resection appears in 1,140 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 33.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 133 | 33.5 | 33.5 |
| Infliximab | 219 | 22.4 | 22.4 |
| Vedolizumab | 88 | 20.1 | 20.1 |
| Ustekinumab | 102 | 19.9 | 19.9 |
| Azathioprine | 87 | 19.4 | 19.5 |
| Adalimumab-Aaty | 41 | 16.4 | 16.4 |
| Adalimumab-Fkjp | 39 | 15.9 | 15.9 |
| Upadacitinib | 66 | 15.6 | 15.6 |
| Adalimumab-Adaz | 40 | 14.3 | 14.3 |
| Infliximab-Dyyb | 22 | 14.0 | 14.0 |
| Adalimumab | 358 | 13.0 | 13.0 |
| Tapentadol Hydrochloride | 9 | 4.9 | 4.9 |